Korean J Nephrol.
2004 May;23(3):528-531.
Pure Red-Cell Aplasia Due to Antibodies Against Erythropoietin
- Affiliations
-
- 1Department of Internal Medicine, and Clinical Research Institute, Soonchunhyang University, Chonan, Korea. eylee@sch.ac.kr
- 2Department of Clinical Pathology, College of Medicine, Soonchunhyang University, Chonan, Korea.
Abstract
- Recombinant human erythropoietin (rHuEPO) is extensively used in anemic patients on dialysis. We experienced a case of pure red-cell aplasia (PRCA) caused by anti-rHuEPO Antibody. A 48-year-old male with CRF was placed on chronic hemodialysis. He developed severe anemia (Hb 6.6 g/dL) without any apparent blood loss. A transfusion was given and the rHuEPO dose was increased to 12, 000 U/week SC. A bone marrow study was carried out. Anti-rHuEPO antibodies were positive. rHuEPO therapy was stopped. No improvement in the anemia was apparent. Although very rare, anti-rHuEPO antibodies should be evaluated in patients with severe anemia without obvious etiology.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Pure Red Cell Aplasia in Pregnancy
- Two Cases of Pure Red Cell Aplasia Due to Anti-erythropoietin Antibodies
- Acquired Pure Red Cell Aplasia due to Anti-Erythropoietin Antibodies in a Patient Undergoing Hemodialysis
- Successful Erythropoietin Therapy after Alemtuzumab and Cyclosporin a Treatment for Epoetin-Induced Pure Red Cell Aplasia
- Erythropoietin Antibody-Positive Pure Red Cell Aplasia Diagnosed after Surgical Intervention for Malignant Gastric Ulcer Bleeding
